Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mercedes Gonzalez

Dermatology Miami, FL Medical Doctor

NPI 1750563243 CMS profile 306248

1150 Nw 14Th St Fl 2, Miami, FL 33136

Open in the dashboard

General payments

$942,964

1,204 records reported · program years 2019–2025

Research payments

$301,304

Paid to them · 43 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,641,528 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mercedes Gonzalez of Miami, FL is reported in the CMS Open Payments database as having received $942,964 across 1,204 general payments and $301,304 in research payments paid to them. Separately, studies naming them as principal investigator received $2,641,528 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $339,861 364
2025 Research $117,937 9
2024 General $262,680 251
2024 Research $171,734 6
2023 General $137,828 175
2022 General $34,230 110
2022 Research $11,033 26
2021 General $28,485 89
2021 Research $599 2
2020 General $23,384 60
2019 General $116,496 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mercedes Gonzalez
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Mercedes Gonzalez were reported at $339,861. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Mercedes Gonzalez Dermatology median Middle half National median
2019 $116,496 $454 $129–$1,240 $163
2020 $23,384 $235 $81–$756 $114
2021 $28,485 $377 $108–$1,108 $132
2022 $34,230 $514 $143–$1,391 $149
2023 $137,828 $607 $159–$1,674 $160
2024 $262,680 $751 $204–$1,903 $164
2025 $339,861 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $153,069 187 payments
  2. Genzyme Corporation $148,568 130 payments
  3. Lilly USA, LLC $92,128 96 payments
  4. Pfizer Inc. $68,517 114 payments
  5. Galderma Laboratories, L.P. $61,121 91 payments
  6. Regeneron Pharmaceuticals, Inc. $54,575 51 payments
  7. AbbVie, Inc. $52,433 90 payments
  8. Arcutis Biotherapeutics, Inc. $50,152 35 payments
  9. Organon LLC $44,060 49 payments
  10. Krystal Biotech Inc $42,480 40 payments
  11. Other $175,861 321 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $452,594 163 payments
  2. Consulting Fee $343,648 97 payments
  3. Travel and Lodging $74,259 189 payments
  4. Honoraria $44,030 14 payments
  5. Food and Beverage $28,063 732 payments
  6. Education $369 9 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $106,207 117 payments
  2. DUPIXENT Inflammation And Immunology $102,538 143 payments
  3. EBGLYSS $66,069 46 payments
  4. DUPIXENT Immunology And Inflammation $59,900 57 payments
  5. VTAMA $58,405 56 payments
  6. RINVOQ $47,570 64 payments
  7. CIBINQO $46,035 65 payments
  8. Zoryve $45,985 31 payments
  9. VYJUVEK $42,480 40 payments
  10. YCANTH $39,649 26 payments
  11. Other $170,524 505 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nielsen BioSciences, Inc. $274,687 2 payments
  2. Regeneron Pharmaceuticals, Inc. $20,397 34 payments
  3. Pfizer Inc. $4,470 3 payments
  4. Genzyme Corporation $1,750 4 payments

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$2,105

Medicare's payments for the services billed

Medicare patients

11

Average age 73

Services billed

25

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 0%
Chronic kidney disease 0%
COPD 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAPINAROF
$27,820 — —
YCANTH
$26,970 — —
DUPIXENT
$22,247 — —
VYJUVEK
$21,338 — —
Zoryve
$18,003 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

1,247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record